Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360471 | 0.88 | CYP1A2 (0.40) | SMN1; SMN2GAAKDM4ECYP1A2HSD17B10 | |
| SCHEMBL8629548 | 0.81 | MAPK1 (0.52) | SMN1; SMN2KDM4ECYP1A2NPSR1HSD17B10 | |
| SCHEMBL7499654 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| SCHEMBL10878348 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| SCHEMBL8801602 | 0.75 | CYP1A2 (0.40) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| SCHEMBL7292311 | 0.74 | KDM4E (0.31) | KDM4E | |
| SCHEMBL7505743 | 0.74 | KDM4E (0.41) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| Bicarbonate SCHEMBL11820621 | 0.74 | ADORA3 (0.37) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| SCHEMBL6980632 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2GAAKDM4ELMNACYP1A2 | |
| SCHEMBL12481306 | 0.70 | CYP1A2 (0.43) | SMN1; SMN2GAAKDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401432-A1 | THERAPEUTIC METHODS, COMBINATIONS AND KITS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2022-12-22 | — | — | US | disclosed |
| EP-0634405-B1 | Pyrimidinyl acrylic acid derivatives, process for their preparation and their use for the control of phytopathogens | BAYER AG (DE) | 2002-10-30 | — | — | EP | disclosed |
| US-5635508-A | FUNGICIDES | NOVARTIS AG (CH) | 1997-06-03 | — | — | US | disclosed |
| US-5453427-A | Control phytopathogenic fungi especially in monocotelydons, podery mildew and rust | SANDOZ LTD. (CH) | 1995-09-26 | — | — | US | disclosed |
| EP-0634405-A1 | Pyrimidinyl acrylic acid derivatives, process for their preparation and their use for the control of phytopathogens | SANDOZ LTD. (CH) | 1995-01-18 | — | — | EP | disclosed |
| US-5089490-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| US-4758556-A | Cephem derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0194571-A1 | Heterocyclic disulfides, process for their preparation and pharmaceutical preparations containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-09-17 | — | — | EP | disclosed |
| US-4278793-A | ANTIBIOTICS, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401432-A1 | THERAPEUTIC METHODS, COMBINATIONS AND KITS | MMP8, TLR7, GOT2 | SMN1; SMN2 1529/4885GAA 107/4885KDM4E 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.